John Kenneth Jenkins
CIK: 0001742557
Associated companies
Transaction History
| CRBP | ▼ Sell | Open Market | 4,800 | $38K | 6/10/2026 | View on chart |
| CRBP | ▲ Buy | Grant | 3,800 | $0 | 5/19/2026 | View on chart |
| CRBP | ▼ Sell | Open Market | 2,783 | $20K | 5/30/2025 | View on chart |
| CRBP | ▲ Buy | Grant | 4,800 | $0 | 5/30/2025 | View on chart |
| CRBP | ▲ Buy | Grant | 2,783 | $0 | 5/30/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Corbus Doses First Patient in CRB-701 TEMPO-1 Study
Corbus Pharmaceuticals announced that the first patient has been dosed in the TEMPO-1 registrational study for CRB-701. This clinical trial focuses on patients with second-line or later oropharyngeal cancer. The update marks a significant step in the development timeline for the company's lead asset.
Corbus Doses First Patient in CRB-701 TEMPO-1 Study. Corbus Pharmaceuticals announced that the first patient has been dosed in the TEMPO-1 registrational study for CRB-701. This clinical trial focuses on patients with second-line or later oropharyngeal cancer. The update marks a significant step in the development timeline for the company's lead asset.